The definition of long COVID used in interventional studies
Introduction There has been little consensus for a specific definition of long COVID, though several organizations have created varying ones. We sought to examine the definition of long COVID used in ongoing clinical trials. Methods We searched ‘long COVID’ and related terms on both PubMed and clini...
Gespeichert in:
| Veröffentlicht in: | European journal of clinical investigation 2023-08, Vol.53 (8), p.e13989-n/a |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 8 |
| container_start_page | e13989 |
| container_title | European journal of clinical investigation |
| container_volume | 53 |
| creator | Haslam, Alyson Olivier, Timothée Prasad, Vinay |
| description | Introduction
There has been little consensus for a specific definition of long COVID, though several organizations have created varying ones. We sought to examine the definition of long COVID used in ongoing clinical trials.
Methods
We searched ‘long COVID’ and related terms on both PubMed and clinicaltrials.gov for randomized studies that either included patients with long COVID or had a persistent or long‐term COVID‐related outcome and ed long COVID definition components.
Results
Of the 92 studies, a laboratory‐only confirmed diagnosis of COVID‐19 was stipulated in 54.3% (n = 50) studies. We found eight different time durations specified for how long symptoms needed to have occurred, ranging from 4 to 52 weeks, with 12 weeks being the most common (34.8%; n = 32). 35.9% (n = 33) did not specify a time duration. There were 57 different symptoms specified in total, with a median of one symptom identified per study (range 0–32). 8.7% of trials adhered to NICE or WHO definitions.
Conclusion
Standardized definitions of long COVID should be applied in studies assessing this condition to unify and harmonize research on this topic. |
| doi_str_mv | 10.1111/eci.13989 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2791381858</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2840106092</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3539-ac4269d25f7a8b80fc2f7b32f2a904ee0e61d940a61cd01195cb5e22dc87b70f3</originalsourceid><addsrcrecordid>eNp10E1LAzEQBuAgiq3Vg39AFrzoYdt87EeCJ1mrFgq9VK8hm0w0Zburm12l_97UVg-Cw8BcHl6GF6FzgsckzAS0GxMmuDhAQ8KyNKYso4doiDFJYipyOkAn3q8wxpwweowGLBNZIkQ6RDfLV4gMWFe7zjV11NioauqXqFg8z-6i3oOJXB22g_YD6i1RVeS73jjwp-jIqsrD2f6O0NP9dFk8xvPFw6y4nceapUzESic0E4amNle85NhqavOSUUuVwAkAhowYkWCVEW0wISLVZQqUGs3zMseWjdDVLvetbd578J1cO6-hqlQNTe8lzQVhnPCUB3r5h66avg0_B8UTTHCGBQ3qeqd023jfgpVvrVurdiMJlttGZWhUfjca7MU-sS_XYH7lT4UBTHbg01Ww-T9JTovZLvILX0N9nA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2840106092</pqid></control><display><type>article</type><title>The definition of long COVID used in interventional studies</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Haslam, Alyson ; Olivier, Timothée ; Prasad, Vinay</creator><creatorcontrib>Haslam, Alyson ; Olivier, Timothée ; Prasad, Vinay</creatorcontrib><description>Introduction
There has been little consensus for a specific definition of long COVID, though several organizations have created varying ones. We sought to examine the definition of long COVID used in ongoing clinical trials.
Methods
We searched ‘long COVID’ and related terms on both PubMed and clinicaltrials.gov for randomized studies that either included patients with long COVID or had a persistent or long‐term COVID‐related outcome and ed long COVID definition components.
Results
Of the 92 studies, a laboratory‐only confirmed diagnosis of COVID‐19 was stipulated in 54.3% (n = 50) studies. We found eight different time durations specified for how long symptoms needed to have occurred, ranging from 4 to 52 weeks, with 12 weeks being the most common (34.8%; n = 32). 35.9% (n = 33) did not specify a time duration. There were 57 different symptoms specified in total, with a median of one symptom identified per study (range 0–32). 8.7% of trials adhered to NICE or WHO definitions.
Conclusion
Standardized definitions of long COVID should be applied in studies assessing this condition to unify and harmonize research on this topic.</description><identifier>ISSN: 0014-2972</identifier><identifier>EISSN: 1365-2362</identifier><identifier>DOI: 10.1111/eci.13989</identifier><identifier>PMID: 36964995</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Clinical trials ; COVID long‐haulers ; COVID-19 ; Humans ; long COVID ; persistent COVID ; Post-Acute COVID-19 Syndrome ; randomized studies</subject><ispartof>European journal of clinical investigation, 2023-08, Vol.53 (8), p.e13989-n/a</ispartof><rights>2023 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd</rights><rights>2023 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.</rights><rights>Copyright © 2023 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3539-ac4269d25f7a8b80fc2f7b32f2a904ee0e61d940a61cd01195cb5e22dc87b70f3</citedby><cites>FETCH-LOGICAL-c3539-ac4269d25f7a8b80fc2f7b32f2a904ee0e61d940a61cd01195cb5e22dc87b70f3</cites><orcidid>0000-0002-6110-8221 ; 0000-0002-7876-3978 ; 0000-0002-6936-5783</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Feci.13989$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Feci.13989$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36964995$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Haslam, Alyson</creatorcontrib><creatorcontrib>Olivier, Timothée</creatorcontrib><creatorcontrib>Prasad, Vinay</creatorcontrib><title>The definition of long COVID used in interventional studies</title><title>European journal of clinical investigation</title><addtitle>Eur J Clin Invest</addtitle><description>Introduction
There has been little consensus for a specific definition of long COVID, though several organizations have created varying ones. We sought to examine the definition of long COVID used in ongoing clinical trials.
Methods
We searched ‘long COVID’ and related terms on both PubMed and clinicaltrials.gov for randomized studies that either included patients with long COVID or had a persistent or long‐term COVID‐related outcome and ed long COVID definition components.
Results
Of the 92 studies, a laboratory‐only confirmed diagnosis of COVID‐19 was stipulated in 54.3% (n = 50) studies. We found eight different time durations specified for how long symptoms needed to have occurred, ranging from 4 to 52 weeks, with 12 weeks being the most common (34.8%; n = 32). 35.9% (n = 33) did not specify a time duration. There were 57 different symptoms specified in total, with a median of one symptom identified per study (range 0–32). 8.7% of trials adhered to NICE or WHO definitions.
Conclusion
Standardized definitions of long COVID should be applied in studies assessing this condition to unify and harmonize research on this topic.</description><subject>Clinical trials</subject><subject>COVID long‐haulers</subject><subject>COVID-19</subject><subject>Humans</subject><subject>long COVID</subject><subject>persistent COVID</subject><subject>Post-Acute COVID-19 Syndrome</subject><subject>randomized studies</subject><issn>0014-2972</issn><issn>1365-2362</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10E1LAzEQBuAgiq3Vg39AFrzoYdt87EeCJ1mrFgq9VK8hm0w0Zburm12l_97UVg-Cw8BcHl6GF6FzgsckzAS0GxMmuDhAQ8KyNKYso4doiDFJYipyOkAn3q8wxpwweowGLBNZIkQ6RDfLV4gMWFe7zjV11NioauqXqFg8z-6i3oOJXB22g_YD6i1RVeS73jjwp-jIqsrD2f6O0NP9dFk8xvPFw6y4nceapUzESic0E4amNle85NhqavOSUUuVwAkAhowYkWCVEW0wISLVZQqUGs3zMseWjdDVLvetbd578J1cO6-hqlQNTe8lzQVhnPCUB3r5h66avg0_B8UTTHCGBQ3qeqd023jfgpVvrVurdiMJlttGZWhUfjca7MU-sS_XYH7lT4UBTHbg01Ww-T9JTovZLvILX0N9nA</recordid><startdate>202308</startdate><enddate>202308</enddate><creator>Haslam, Alyson</creator><creator>Olivier, Timothée</creator><creator>Prasad, Vinay</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6110-8221</orcidid><orcidid>https://orcid.org/0000-0002-7876-3978</orcidid><orcidid>https://orcid.org/0000-0002-6936-5783</orcidid></search><sort><creationdate>202308</creationdate><title>The definition of long COVID used in interventional studies</title><author>Haslam, Alyson ; Olivier, Timothée ; Prasad, Vinay</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3539-ac4269d25f7a8b80fc2f7b32f2a904ee0e61d940a61cd01195cb5e22dc87b70f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Clinical trials</topic><topic>COVID long‐haulers</topic><topic>COVID-19</topic><topic>Humans</topic><topic>long COVID</topic><topic>persistent COVID</topic><topic>Post-Acute COVID-19 Syndrome</topic><topic>randomized studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Haslam, Alyson</creatorcontrib><creatorcontrib>Olivier, Timothée</creatorcontrib><creatorcontrib>Prasad, Vinay</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Haslam, Alyson</au><au>Olivier, Timothée</au><au>Prasad, Vinay</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The definition of long COVID used in interventional studies</atitle><jtitle>European journal of clinical investigation</jtitle><addtitle>Eur J Clin Invest</addtitle><date>2023-08</date><risdate>2023</risdate><volume>53</volume><issue>8</issue><spage>e13989</spage><epage>n/a</epage><pages>e13989-n/a</pages><issn>0014-2972</issn><eissn>1365-2362</eissn><abstract>Introduction
There has been little consensus for a specific definition of long COVID, though several organizations have created varying ones. We sought to examine the definition of long COVID used in ongoing clinical trials.
Methods
We searched ‘long COVID’ and related terms on both PubMed and clinicaltrials.gov for randomized studies that either included patients with long COVID or had a persistent or long‐term COVID‐related outcome and ed long COVID definition components.
Results
Of the 92 studies, a laboratory‐only confirmed diagnosis of COVID‐19 was stipulated in 54.3% (n = 50) studies. We found eight different time durations specified for how long symptoms needed to have occurred, ranging from 4 to 52 weeks, with 12 weeks being the most common (34.8%; n = 32). 35.9% (n = 33) did not specify a time duration. There were 57 different symptoms specified in total, with a median of one symptom identified per study (range 0–32). 8.7% of trials adhered to NICE or WHO definitions.
Conclusion
Standardized definitions of long COVID should be applied in studies assessing this condition to unify and harmonize research on this topic.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>36964995</pmid><doi>10.1111/eci.13989</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-6110-8221</orcidid><orcidid>https://orcid.org/0000-0002-7876-3978</orcidid><orcidid>https://orcid.org/0000-0002-6936-5783</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0014-2972 |
| ispartof | European journal of clinical investigation, 2023-08, Vol.53 (8), p.e13989-n/a |
| issn | 0014-2972 1365-2362 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2791381858 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Clinical trials COVID long‐haulers COVID-19 Humans long COVID persistent COVID Post-Acute COVID-19 Syndrome randomized studies |
| title | The definition of long COVID used in interventional studies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T06%3A24%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20definition%20of%20long%20COVID%20used%20in%20interventional%20studies&rft.jtitle=European%20journal%20of%20clinical%20investigation&rft.au=Haslam,%20Alyson&rft.date=2023-08&rft.volume=53&rft.issue=8&rft.spage=e13989&rft.epage=n/a&rft.pages=e13989-n/a&rft.issn=0014-2972&rft.eissn=1365-2362&rft_id=info:doi/10.1111/eci.13989&rft_dat=%3Cproquest_cross%3E2840106092%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2840106092&rft_id=info:pmid/36964995&rfr_iscdi=true |